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Essentials
• Several indexes are available for mixing test interpretation in lupus anticoagulant detection.
• Mixing test-specific cutoff (MTC) and index of circulating anticoagulant (ICA) were used.
• ICA exhibited higher specificity than MTC in nonlupus anticoagulant samples with prolonged clotting times.
• It is important to understand the characteristics of indexes for mixing test interpretation.
| INTRODUCTION
The main symptoms of antiphospholipid syndrome (APS) are vascular thrombosis or pregnancy morbidity, and APS is diagnosed when laboratory assays demonstrate the presence of persistent antiphospholipid (aPL) antibodies in patients presenting with these symptoms. 1, 2 Once APS is diagnosed, long-term anticoagulant therapy is considered because the risk of recurrent thrombosis is high. 3 Because thrombosis and pregnancy are nonspecific for APS, accurate detection of aPL antibodies in clinical laboratories is critical in securing a diagnosis of APS.
Three types of aPL are defined as criteria antibodies in International Society on Thrombosis and Haemostasis (ISTH) guidance. 4 The antibodies detected in solid phase assays are anticardiolipin antibodies and anti-β2-glycoprotein I antibodies and are reported quantitatively.
On the other hand, lupus anticoagulants (LAs) are detected by prolonged clotting times in uncalibrated coagulation assays. 3 A medley of phospholipid-dependent coagulation assays are employed for LA detection; screening tests to detect clotting time prolongation, mixing tests to evidence inhibition, and confirmatory tests to "bypass" the LA and shorten clotting times. Inherent difficulties and interferences with clotting assays complicate LA detection, and guidelines with broad but not complete agreement are available to lead best practice. [5] [6] [7] All guidelines acknowledge that no single assay system will detect all LAs, and 2 different-principle assays are recommended for LA detection. The first test considered is diluted Russell's viper venom time (dRVVT), which is considered specific for LA detection in high-thrombosis-risk patients, 8 and the second test should be an LA-sensitive activated partial thromboplastin time (APTT). Testing order has proven controversial, and while ISTH guidelines recommend the traditional screen, then mix to detect inhibition and confirm only if the mix is positive, 5, 6, 9 other expert panels recommend alternative approaches.
Concerns about false-negative mixing tests due to the dilution effect resulted in the Clinical and Laboratory Standards Institute guideline recommending initial measurement of screening and confirmation tests to evidence the phospholipid dependence of LA and performance of mixing tests when screening/confirmation test results are not clear-cut. 7, 9 The British Society for Haematology guidelines suggest performing the full medley but indicate that apparently normal mixing tests can be disregarded in certain circumstances. In all guidelines, the mixing test is recommended, and it is useful and important for demonstrating the presence of LA and differentiating the inhibitor from a factor deficiency.
Two mixing test interpretation methods, mixing test-specific cutoff (MTC) and the index of circulating anticoagulant (ICA) were described in the guidelines. MTC is derived from the upper limit of population distribution data for screening test ratios performed on 1:1 mixtures with a common normal pooled plasma. Ratios are calculated as: 1:1 mix sample (seconds)/1:1 mix reference interval mean (seconds). The formula for ICA is ([1:1 Mix Sample (seconds) − Normal Pooled Plasma (seconds)]/Screen Patient (seconds)) × 100. Because weaker LA can generate negative mixing tests despite clear screen and confirm positivity in undiluted plasma, 6, 7, 10, 11 it is crucial to perform mixing tests with high sensitivity reagents and an appropriate index. Aside from low-potency antibodies, false-negative mixing tests can be induced by a less sensitive reagent, higher cutoff values, and some clinical conditions. We previously reported higher sensitivity to LA with MTC than ICA with multiple APTT and dRVVT reagents. 12 It is important to investigate with multiple reagents because sensitivity and specificity for LA, especially with APTT, varies due to differences in phospholipid composition and concentration. [13] [14] [15] However, that study focused on only sensitivity to known LAs, and specificity was not investigated. There are few data comparing MTC and ICA in the context of LA specificity, and the present study aims to complement the previous study and compare performance of MTC and ICA with multiple reagents in samples with non-LA causes of prolonged clotting times.
| MATERIALS AND METHODS

| Plasma samples
The methods of blood collection and sample preparation were as previously described. 16 Briefly, blood samples were collected into Vacuette tubes (Greiner Bio-One Ltd, Tokyo, Japan), which include a one-tenth volume of 0.105 mol/L (3.2%) trisodium citrate. These samples were double-centrifuged and stored at −80°C until use. The plasma samples were derived from 5 patients with hemophilia A (factor VIII [FVIII], 2.2-10.7 IU/dL), 4 with hemophilia B (factor IX [FIX], <1-23.8 IU/dL), one with factor XII (FXII) deficiency (FXII, 39.9 IU/dL), and 25 non-APS warfarinized patients with a prolonged APTT using an LA-insensitive reagent (see below). In addition, 6 samples with FVIII inhibitors were included (1.02-69.76 NBU/mL). Plasmas from 6 patients anticoagulated with direct factor Xa (FXa) inhibitors (5 on rivaroxaban, 1 on apixaban) for reasons other than APS were also tested. The drug concentrations were 15 to 54 and 295 ng/mL, respectively. For further analysis, artificial factor-deficiency samples were prepared to assess specificity at different degrees of single-factor reductions. Lyophilized plasmas, immunodepleted of single coagulation factors II, V, VIII, IX, X, XI, or XII (Siemens Healthineers, Erlanger, Germany) were mixed with standard human plasma (Siemens Healthineers) to produce 6 samples for each factor at concentrations of <1%, 1%, 2%, 5%, 10%, and 20%. The levels of the nondepleted factors have previously been shown to be normal in these lyophilized plasmas. 17 The <1% factor II plasma was excluded from data analysis because of a no-coagulation error.
| Coagulation screening tests
Prothrombin time (PT), APTT, fibrinogen by the Clauss method, and thrombin time were performed as coagulation screening tests.
The reagents were Dade Innovin, Actin FS, Thrombin-Reagent, and Thromboclotin (Siemens Healthineers), respectively. All tests were performed in a Sysmex CS-2100i (Sysmex UK, Milton Keynes, UK). CS-2400 (Sysmex Corporation). The compositional characteristics of each reagent were previously described. 12 All clotting time results were determined once, as imprecision is low with automated coagulometers. 
| Reagents for mixing tests
| Mixing tests and the cutoff values
| Mixing tests algorithm for deficient and inhibitor samples
The mixing test algorithm for factor-deficient and inhibitor samples is shown in Figure 1 . All factor-deficient and inhibitor samples were analyzed with each reagent. Samples were divided into 3 groups: (1) 
| RESULTS
| Screen ratios, mix ratios, and ICA in each reagent
The numbers of samples with elevated screen ratios with each reagent and their mixing test results are shown in 
| The percentage of corrected and not-corrected samples in MTC and ICA
Theoretically, the factor-deficient and warfarin samples should achieve corrected mixing test results. The frequencies of corrected (Table 4 ).
| DISCUSSION
Although recommendations for test order vary among the 3 current LA guidelines, mixing tests are recommended in all 3 despite acknowledged limitations, so there is value in maximizing diagnostic performance. [5] [6] [7] The present study investigated performance of mixing studies on non-LA plasma samples with elevated screen ratios in APTT, dAPTT, and/or dRVVT prior to dilution in NPP to evaluate specificity of the 2 recommended mixing test interpretive parameters in LA detection, MTC, and ICA.
A higher frequency of corrected mixing tests in samples with reduced coagulation factor levels was encountered when applying ICA than MTC in all reagents except PTT, which exhibited a similar frequency of corrected values for both ICA and MTC. High specificity for ICA has been previously described for multiple-LA-sensitive APTT reagents when comparing samples with reduced coagulation factor levels against those known to contain LA. 19 However, recent studies have shown that ICA is less sensitive than MTC to the presence of LA in multiple reagents. 12, 16, 20 The most likely explanation for the apparent reduced specificity of MTC is that the broad principle of mixing tests expects that 50% of a given factor is sufficient to (A) The coagulation factor-deficient group includes artificially prepared plasmas deficient in single coagulation factor II, V, VIII, IX, X, XI or XII, hereditary deficiencies of factors VIII, IX, and XII, and warfarin. The numbers of samples with elevated screen ratios in undiluted samples are presented because mixing tests are performed only when the initial screen is elevated. The percentage of samples with elevated initial screen ratios in undiluted plasma was calculated in APTT/dAPTT and dRVVT. The total numbers with elevated initial screens were 76 and 42, respectively. The sample groups were the same as Table 2 . (B) The inhibitor group includes samples containing factor VIII inhibitors and the direct factor Xa inhibitors rivaroxaban and apixaban. The total number of samples with elevated initial screen ratios were 12 and 6 for APTT and dRVVT, respectively. The sample groups were the same as Table 2 . such that a more marked deficiency may well return into the reference range for undiluted plasma but not the mixing test range.
Mixing tests serve to differentiate between inhibitors and factor deficiencies, 21 -23 yet they are not specific for LA-induced inhibition, which is the role of confirmatory tests, so samples containing FVIII inhibitors and direct FXa inhibitors were included in this study.
Although FVIII inhibitors are progressive, sufficiently potent or avid antibodies can manifest in immediate APTT mixing tests, 22 which was encountered in some of the samples in this study. Similarly, direct FXa inhibitors have inevitably been shown to prolong APTT and dRVVT measurements in undiluted plasma and mixing tests. [24] [25] [26] [27] The frequencies of elevated MTC and ICA in the multiple reagents were 29% to 100% and 25% to 67%, respectively, attesting to the lower sensitivity of ICA to the presence of inhibition compared to MTC.
Manifestation of direct FXa inhibitors in a given assay and its mixing
test is a function of drug concentration and reagent responsiveness.
Rivaroxaban and apixaban are inhibitory by design and ex vivo samples with a range of drug concentrations were employed to assess detection of direct FXa inhibitor-induced inhibition. 26 Samples from patients on edoxaban and dabigatran were not locally available but not-corrected mixing tests have been previously demonstrated. 28 As direct oral anticoagulant (DOAC) levels are infrequently performed in the clinical diagnostic setting, the number of DOAC-containing samples was limited in this study and further work is planned to achieve a wider assessment of DOAC interference in mixing tests with multiple reagents. In addition, an attempt to establish thresholds with best balances between sensitivity and specificity for factor deficiency and inhibitor in each mixing test index is planned.
Based on the greater specificity for non-LA causes of prolonged clotting times with ICA but greater sensitivity to inhibition for MTC, we suggest LA diagnostic algorithms incorporating different approaches, depending on whether the APTT reagent in use has high or low LA sensitivity (Figure 2 ). In the routine coagulation screening tests for this study, Actin FS, recognized as an LA-insensitive APTT reagent, was used in our laboratory. 29 When the clotting time is prolonged with Actin FS in a nonanticoagulated patient, factor deficiency is considered first, as LA is largely excluded, with recognition that potent LA can elevate The number of samples with elevated initial screen ratios in undiluted plasmas for both deficient and inhibitor groups for APTT/dAPTT and dRVVT were 88 and 48, respectively. The consistent identification percentages were calculated from the total number of samples in both deficient and inhibitor groups. The sample groups were the same as interpreted with ICA due to its superior specificity, as there are few false positives for inhibition when the initial elevated screening test is due to factor deficiency, as shown in Table 4 . When ICA is positive at this juncture, the LA confirmatory test should be performed to complete the medley. In cases of an ICA corrected result, factor deficiency is the first consideration, but the possibility of a weak LA must be borne in mind because of the lower LA sensitivity of ICA compared to MTC. Even if the clotting time or ratio of an LA-sensitive APTT are not prolonged, reagent and antibody heterogeneity require that dRVVT screening also be performed when investigating for LA. [5] [6] [7] When dRVVT screening, confirmation, and mixing tests are examined, MTC should be adopted for mixing test interpretation, as it has superior LA sensitivity to ICA, 12, 16, 20 and common pathway factor deficiencies will have been largely excluded by the APTT investigative approach described above, in tandem with prothrombin time, with acknowledgment that sensitivity of APTT reagents to LA, coagulation deficiency, coagulation inhibitor, and drugs vary because of the compositional differences. 5
There were some limitations in our study, such as the small numbers of samples containing hereditary factor deficiencies, FVIII inhibitors, and direct FXa inhibitors, which may not fully reflect the spread of mixing test results encountered in the routine diagnostic setting. Additionally, while the artificial factor-deficient samples gave an indication of assay behavior at different levels of isolated coagulation factor reductions, they cannot reproduce variability in clinical samples arising from different molecular variants.
In conclusion, ICA exhibited superior specificity to MTC in multiple reagents when investigating non-LA causes of prolonged clotting times. Alternative approaches to adoption of these indexes are proposed based on local approach to routine coagulation screening, with recognition that neither index provides diagnostic certainty.
